Langdon L Miller, MD

Langdon L. Miller, MD has extensive experience in the field of clinical research and development, particularly in the oncology sector. Langdon L currently holds the position of Principal at Sound Clinical Solutions, SP since February 2013. In addition, they serve as the Executive Vice President of Development and Chief Medical Officer at Solve Therapeutics, Inc. starting from October 2021.

Previously, they held leadership roles at various companies. From March 2018 to June 2021, Dr. Miller worked as the Executive Vice President of Development and Chief Medical Officer at VelosBio. Prior to that, they served as the Vice President of Clinical Research, Oncology at Gilead Sciences from April 2011 to January 2013.

Dr. Miller also held executive positions at Calistoga Pharmaceuticals as the Executive Vice President of Research & Development from July 2010 to March 2011, and at PTC Therapeutics, Inc. as the Chief Medical Officer from July 2003 to July 2010.

Earlier in their career, Dr. Miller gained valuable experience at Pharmacia & Upjohn as the Clinical Vice President of Global Clinical Research, Oncology from October 1995 to June 2003. Langdon L began their professional journey at the National Cancer Institute (NCI) where they worked as a Senior Investigator from September 1989 to September 1995.

Overall, Dr. Langdon L. Miller's work experience demonstrates their significant contributions and expertise in the field of clinical research and development within the oncology industry.

Langdon L Miller, MD completed their high school education at Phillips Academy, earning a High School Diploma in 1972. Langdon L then pursued a Post-Graduate Year at Epsom College in 1972-1973. Miller went on to attend Northwestern University - The Feinberg School of Medicine from 1973 to 1979, where they obtained their MD degree in Medicine. Following this, they completed a Residency in Internal Medicine at the University of Minnesota Medical School from 1979 to 1983. Miller then pursued a Fellowship in Tumor Immunology at the University of California, San Francisco - School of Medicine from 1983 to 1985. Finally, they completed another Fellowship in Medical Oncology at Stanford University School of Medicine from 1985 to 1989.